Subject(s)
Leiomyosarcoma , Skin Neoplasms , Humans , Female , Leiomyosarcoma/mortality , Leiomyosarcoma/pathology , Leiomyosarcoma/diagnosis , Skin Neoplasms/mortality , Skin Neoplasms/pathology , Skin Neoplasms/diagnosis , Male , Middle Aged , Aged , Sex Factors , Adult , Health Status Disparities , Aged, 80 and overABSTRACT
BACKGROUND: Field cancerization is poorly defined in dermatology. The author group previously proposed and applied a classification system in an original cohort to risk-stratify patients with field cancerization. OBJECTIVE: Apply the authors' classification system within a validation cohort. METHODS: Patients with keratinocyte carcinoma history completed a survey regarding demographic information, medical history, and chemoprevention use. Patients were assigned a field cancerization class, and differences between validation and original cohorts were assessed. RESULTS: A total of 363 patients were enrolled (mean age 67.4; 61.7% male). After comparing validation and original cohorts, there were differences in age between class II (p = .02) and class IVb (p = .047), and differences in chemoprevention use in class III (p = .04). Similar to the original cohort, the validation cohort was associated with increases in total number of skin cancers in the last year (p < .001), 5 years (p < .001), lifetime (p < .001), years since first skin cancer (p < .001), and chemoprevention use (p < .001). In the validation cohort, there were increases in age (p = .03) and immunocompromised status (p = .04) with increasing class, which were not observed in the original cohort. CONCLUSION: Differences among field cancerization classes were similar in a validation cohort, further highlighting the importance of class-specific treatment and management.
Subject(s)
Leiomyosarcoma , Skin Neoplasms , Humans , Leiomyosarcoma/diagnosis , Leiomyosarcoma/pathology , Leiomyosarcoma/ethnology , Skin Neoplasms/diagnosis , Skin Neoplasms/ethnology , Skin Neoplasms/pathology , Male , Female , Middle Aged , Aged , Ethnicity/statistics & numerical data , Racial Groups/statistics & numerical data , Aged, 80 and overSubject(s)
Asian , Melanoma , Native Hawaiian or Other Pacific Islander , Skin Neoplasms , Adult , Aged , Female , Humans , Male , Middle Aged , Asian/statistics & numerical data , Melanoma/epidemiology , Melanoma/mortality , Melanoma, Cutaneous Malignant , Native Hawaiian or Other Pacific Islander/statistics & numerical data , Sex Factors , Skin Neoplasms/epidemiology , Skin Neoplasms/mortalitySubject(s)
Dermatology , Periodicals as Topic , Transgender Persons , Humans , Dermatology/trends , Dermatology/statistics & numerical data , Cross-Sectional Studies , Transgender Persons/statistics & numerical data , Periodicals as Topic/statistics & numerical data , Periodicals as Topic/trends , Male , FemaleSubject(s)
Alaska Natives , Melanoma , SEER Program , Skin Neoplasms , Humans , Melanoma/epidemiology , Melanoma/ethnology , Female , SEER Program/statistics & numerical data , Skin Neoplasms/epidemiology , Skin Neoplasms/ethnology , Retrospective Studies , Male , Alaska Natives/statistics & numerical data , Middle Aged , United States/epidemiology , Aged , Sex Factors , Adult , Indians, North American/statistics & numerical data , Sex DistributionABSTRACT
Epithelial adenocarcinoma of the ovary and colon are associated with the highest rates of cancer-related deaths in women in the U.S. The literature supports the role of HDL-associated apolipoproteins in the treatment of cancer and other pro-inflammatory diseases. Previously, we developed a novel 20-amino acid mimetic peptide, HM-10/10, which potently inhibits tumor development and growth in colon and ovarian cancer. Here, we report the properties of HM-10/10 relative to its stability in vitro. The results demonstrated that HM-10/10 had the highest half-life in human plasma compared to plasma from other species tested. HM-10/10 demonstrated stability in human plasma and simulated gastric environment, increasing its promise as an oral pharmaceutical. However, under conditions modeling the small intestine, HM-10/10 demonstrated significant degradation, likely due to the peptidases encountered therein. Furthermore, HM-10/10 demonstrated no evidence of time-dependent drug-drug interactions, although it demonstrated CYP450 induction slightly above cutoff. As proteolytic degradation is a common limitation of peptide-based therapeutics, we are pursuing strategies to improve the stability properties of HM-10/10 by extending its bioavailability while retaining its low toxicity profile. HM-10/10 holds promise as a new agent to address the international women's health crisis of epithelial carcinomas of the ovary and colon.
Subject(s)
Neoplasms , Humans , Female , Neoplasms/drug therapy , Neoplasms/pathology , Peptides/pharmacology , Peptides/chemistry , Colon/pathologyABSTRACT
We prove the existence of free objects in certain subcategories of Banach lattices, including p-convex Banach lattices, Banach lattices with upper p-estimates, and AM-spaces. From this we immediately deduce that projectively universal objects exist in each of these subcategories, extending results of Leung, Li, Oikhberg and Tursi (Israel J. Math. 2019). In the p-convex and AM-space cases, we are able to explicitly identify the norms of the free Banach lattices, and we conclude by investigating the structure of these norms in connection with nonlinear p-summing maps.